Tenax Therapeutics (TENX) Retained Earnings (2011 - 2026)
Tenax Therapeutics (TENX) reported Retained Earnings of $497.9 million for Q1 2026, up 14.57% on a YoY basis from $434.6 million in Q1 2025, and up 7.18% sequentially from $464.5 million in Q4 2025.
Tenax Therapeutics (TENX) Retained Earnings (2011 - 2026) Analysis & Trends
Tenax Therapeutics (TENX) has 15 years of Retained Earnings data on file, last reported at $497.9 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 14.57% year-over-year to $497.9 million; the trailing twelve-month figure through Mar 2026 stood at $497.9 million (up 14.57% YoY), and the FY2025 full-year result was $464.5 million, up 247.54% from the prior year.
- Retained Earnings advanced to $497.9 million in Q1 2026, from $464.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $497.9 million in Q1 2026 to a low of -$314.9 million in Q4 2024.
- A 5-year average of $71.4 million and a median of $282.8 million in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 103677543.07% in 2022 and soared 247.54% in 2025, its largest moves.
- Tracing TENX's Retained Earnings over 5 years: stood at -$289.5 million in 2022, then slipped by 2.66% to -$297.3 million in 2023, then dropped by 5.92% to -$314.9 million in 2024, then soared by 247.54% to $464.5 million in 2025, then advanced by 7.18% to $497.9 million in 2026.
- Business Quant data shows TENX's Retained Earnings at $497.9 million in Q1 2026, $464.5 million in Q4 2025, and $448.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Tenax Therapeutics | 67,856.40 | 67,856.40 | - | 497.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 497.86 Mn |
| Dec 31, 2025 | 464.52 Mn |
| Sep 30, 2025 | 448.12 Mn |
| Jun 30, 2025 | 439.44 Mn |
| Mar 31, 2025 | 434.55 Mn |
| Dec 31, 2024 | -314.86 Mn |
| Sep 30, 2024 | 405.81 Mn |
| Jun 30, 2024 | 313.50 Mn |
| Mar 31, 2024 | -301.05 Mn |
| Dec 31, 2023 | -297.25 Mn |
| Sep 30, 2023 | -294.03 Mn |
| Jun 30, 2023 | -292.06 Mn |
| Mar 31, 2023 | -290.95 Mn |
| Dec 31, 2022 | -289.54 Mn |
| Sep 30, 2022 | 290.94 Mn |
| Jun 30, 2022 | -284.08 Mn |
| Mar 31, 2022 | 282.82 Mn |
| Dec 31, 2021 | -278.49 Mn |
| Sep 30, 2021 | 282.52 Mn |
| Jun 30, 2021 | -274.00 |